双歧杆菌三联活菌胶囊对肝性脑病患者肠黏膜屏障功能及血氨的影响

目的 探讨双歧杆菌三联活菌胶囊对肝性脑病患者肠屏障功能及血氨的影响。方法 选取100例确诊为肝性脑病的患者，随机分为对照组和治疗组各50例。对照组患者给予肝性脑病常规综合治疗，治疗组在常规综合治疗的基础上同时口服双歧杆菌三联活菌胶囊进行治疗。治疗前及治疗两周后分别检测两组患者肠黏膜屏障功能及血氨水平并比较其变化。结果 治疗前两组患者肠屏障功能及血氨水平差异无统计学意义（P>0.05）；治疗2周后，治疗组患者的血氨水平、血清二胺氧化酶（DAO）水平、血清内毒素水平（LPS）及肿瘤坏死因子-α（TNF-α）水平较治疗前显著降低，且较对照组治疗后的水平亦有明显的降低（P＜0.05）。结论 肝性脑病患者在常规综合治疗的基础上，加用双歧杆菌三联活菌胶囊可以明显改善患者肠黏膜屏障功能，减少肠源性血氨的生成，临床疗效确切。

Effects of Viable Triple Bifid Capsule on intestinal mucosal barrier function and blood ammonia of patients with hepatic encephalopathy

Objective To observe the effects of Viable Triple Bifid Capsule on intestinal mucosal barrier function and blood ammonia of patients with hepatic encephalopathy. Methods 100 cases of confirmed hepatic encephalopathy were randomly divided into therapy group (50 cases) or control group (50 cases). The control group received conventional comprehensive therapy while the therapy group received the conventional comprehensive therapy combined with Viable Triple Bifid Capsules. The intestinal mucosal barrier function and the level of blood ammonia were observed and compared respectively at the day before the treatment and two weeks after the treatment. Results Before the treatment, the intestinal mucosal barrier function and the level of blood ammonia did not show significant difference between the two groups. After the treatment, the levels of serum blood ammonia, DAO, endotoxin and TNF-α in the therapy group were significantly lower as compared with those before the treatment and with those in the control group. Conclusion On the basis of the conventional comprehensive therapy, Viable Triple Bifid Capsule can effectively improve intestinal mucosal barrier function and reduce enterogenic ammonia, and achieve satisfactory clinical efficacy.